Paradigm Biopharmaceuticals 과거 수익 실적
과거 기준 확인 0/6
Paradigm Biopharmaceuticals's earnings have been declining at an average annual rate of -29.1%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been declining at an average rate of 73.9% per year.
주요 정보
-29.1%
수익 성장률
-19.5%
EPS 성장률
Biotechs 산업 성장 | 9.6% |
매출 성장률 | -73.9% |
자기자본 수익률 | -246.4% |
순이익 | n/a |
최근 수익 업데이트 | 30 Jun 2024 |
최근 과거 실적 업데이트
Recent updates
Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business
Aug 22Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation
Apr 17Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth
Sep 21Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation
Jun 20Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth
Dec 02Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth
Jun 07Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?
Feb 22We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn
Jan 24Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?
Dec 28When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?
Nov 29수익 및 비용 분석
Paradigm Biopharmaceuticals 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Jun 24 | 0 | -59 | 7 | 58 |
31 Mar 24 | 0 | -64 | 6 | 65 |
31 Dec 23 | 0 | -69 | 6 | 71 |
30 Sep 23 | 0 | -60 | 7 | 62 |
30 Jun 23 | 0 | -52 | 7 | 53 |
31 Mar 23 | 0 | -48 | 9 | 48 |
31 Dec 22 | 0 | -44 | 10 | 43 |
30 Sep 22 | 0 | -42 | 9 | 41 |
30 Jun 22 | 0 | -39 | 9 | 39 |
31 Mar 22 | 0 | -40 | 9 | 39 |
31 Dec 21 | 0 | -41 | 10 | 40 |
30 Sep 21 | 0 | -37 | 10 | 37 |
30 Jun 21 | 0 | -34 | 10 | 34 |
31 Mar 21 | 0 | -31 | 7 | 30 |
31 Dec 20 | -1 | -28 | 5 | 27 |
30 Sep 20 | 0 | -20 | 4 | 20 |
30 Jun 20 | 0 | -12 | 3 | 14 |
31 Mar 20 | 2 | -14 | 4 | 12 |
31 Dec 19 | 4 | -16 | 4 | 9 |
30 Sep 19 | 3 | -16 | 4 | 8 |
30 Jun 19 | 3 | -16 | 4 | 8 |
31 Mar 19 | 3 | -11 | 3 | 7 |
31 Dec 18 | 3 | -7 | 3 | 7 |
30 Sep 18 | 3 | -7 | 2 | 7 |
30 Jun 18 | 3 | -6 | 2 | 7 |
31 Mar 18 | 2 | -6 | 2 | 6 |
31 Dec 17 | 2 | -5 | 2 | 5 |
30 Sep 17 | 2 | -5 | 2 | 5 |
30 Jun 17 | 2 | -4 | 2 | 4 |
31 Mar 17 | 2 | -4 | 2 | 4 |
31 Dec 16 | 1 | -4 | 2 | 4 |
30 Sep 16 | 1 | -4 | 2 | 3 |
30 Jun 16 | 1 | -3 | 1 | 3 |
31 Mar 16 | 1 | -3 | 2 | 2 |
31 Dec 15 | 0 | -2 | 1 | 1 |
30 Sep 15 | 0 | -2 | 1 | 1 |
30 Jun 15 | 0 | -2 | 1 | 0 |
양질의 수익: PAR is currently unprofitable.
이익 마진 증가: PAR is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: PAR is unprofitable, and losses have increased over the past 5 years at a rate of 29.1% per year.
성장 가속화: Unable to compare PAR's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: PAR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.5%).
자기자본 수익률
높은 ROE: PAR has a negative Return on Equity (-246.38%), as it is currently unprofitable.